The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells-Reference-Cited by-同舟云学术

The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells

Published:2014-02-11 Issue:5 Volume:110 Page:1278-1287
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Henderson D J P,Byrne A,Dulla K,Jenster G,Hoffmann R,Baillie G S,Houslay M D

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc201422.pdf

Reference50 articles.

1. Amorino GP, Parsons SJ (2004) Neuroendocrine cells in prostate cancer. Crit Rev Eukaryot Gene Expr 14 (4): 287–300.

2. Bolger G, Erdogan S, Jones R, Loughney K, Scotland G, Hoffmann R, Wilkinson I, Farrell C, Houslay M (1997) Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. Biochem J 328 (2): 539–548.

3. Cho-Chung YS, Nesterova MV (2005) Tumor reversion: protein kinase a isozyme switching. Ann N Y Acad Sci 1058 (1): 76–86.

4. Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76: 481–511.

5. Desiniotis A, Schäfer G, Klocker H, Eder IE (2010) Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A. Int J Cancer 126 (3): 775–789.

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Propensity to trust shapes perceptions of comforting touch between trustworthy human and robot partners;Scientific Reports;2024-03-21

2. Elevated PDE4C level serves as a candidate diagnostic biomarker and correlates with poor survival in thyroid carcinoma;Scientific Reports;2024-03-21

3. cAMP‐phosphodiesterase 4D7 (PDE4D7) forms a cAMP signalosome complex with DHX9 and is implicated in prostate cancer progression;Molecular Oncology;2024-01-05

4. Revisiting the roles of cAMP signalling in the progression of prostate cancer;Biochemical Journal;2023-10-13

5. Reduced PDE4D7 in prostate cancer correlates with genomic downregulation within the upstream PDE4D coding region;Future Science OA;2023-10